Limits...
Prophylactic aminophylline for prevention of apnea at higher-risk preterm neonates.

Armanian AM, Badiee Z, Afghari R, Salehimehr N, Hassanzade A, Sheikhzadeh S, Sharif Tehrani M, Rezvan G - Iran Red Crescent Med J (2014)

Bottom Line: Three and four neonates (11.5%, 15.4%) in the aminophylline group developed bradycardia and cyanosis respectively, as compared to 16 infants (61.5%) who did not receive aminophylline (P < 0.001).No side effects were reported in neonates (P > 0.999).In other words, the more premature an infant, the greater the preventative effect of aminophylline on the incidence of apnea and bradycardia.

View Article: PubMed Central - PubMed

Affiliation: Department of Pediatrics, Child Growth and Development Research Center, Isfahan University of Medical Sciences, Isfahan, IR Iran.

ABSTRACT

Background: A few studies have been carried on preventive drugs for apnea of preterm neonates.

Objectives: This study aimed to assess the safety and prophylactic effects of aminophylline on the incidence of apnea in premature neonates.

Patients and methods: This study was a randomized clinical trial (RCT) research. The prophylactic effect of aminophylline on apnea was investigated in premature babies in our NICU (IRAN-Isfahan). In the study group (A), 5 mg/kg aminophylline was initially administered as a loading dose. Then, every 8 hours, 1.5 mg/kg was given as maintenance dose for the next 10 days. In the control group (C), no aminophylline was used during the first ten days of life.

Results: Fifty-two neonates were randomized for the study and all of them completed it. Primary outcomes were clearly different between the two groups. Only 2 infants (7.7%) who had been placed in aminophylline group developed apnea, as compared to 16 infants (61.5%) in the control group (P < 0.001). Three and four neonates (11.5%, 15.4%) in the aminophylline group developed bradycardia and cyanosis respectively, as compared to 16 infants (61.5%) who did not receive aminophylline (P < 0.001). Median time of need to NCPAP (Nasal Continuous Positive Airway Pressure) was 1 (0 - 4) days and 2.5 (0.5 - 6.5) days in group A and C, respectively (P = 0.03). No side effects were reported in neonates (P > 0.999). Median time of hospitalization was shorter in aminophylline group (P = 0.04).

Conclusions: This study supports the preventative effects of aminophylline on apnea in extreme premature infants. In other words, the more premature an infant, the greater the preventative effect of aminophylline on the incidence of apnea and bradycardia.

No MeSH data available.


Related in: MedlinePlus

Consort Diagram Showing the Flow of Samples Through Each Stage of Study.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4221998&req=5

fig12764: Consort Diagram Showing the Flow of Samples Through Each Stage of Study.

Mentions: In our study, 52 neonates were randomized and completed the study (Figure 1), and the results were analyzed with the intention of health promotion and treatment. Demographic characteristics were similar between the two groups (Table 1). Primary outcomes were clearly different between two groups. Two infants (7.7%) in the aminophylline group developed apnea, as compared to 16 infants (61.5%) in the control group (P < 0.001; Table 2). Three and four neonates (11.5%, 15.4%) in the aminophylline group developed bradycardia and cyanosis respectively, as compared to 16 infants (61.5%) in the control group (P < 0.001; Table 2).


Prophylactic aminophylline for prevention of apnea at higher-risk preterm neonates.

Armanian AM, Badiee Z, Afghari R, Salehimehr N, Hassanzade A, Sheikhzadeh S, Sharif Tehrani M, Rezvan G - Iran Red Crescent Med J (2014)

Consort Diagram Showing the Flow of Samples Through Each Stage of Study.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4221998&req=5

fig12764: Consort Diagram Showing the Flow of Samples Through Each Stage of Study.
Mentions: In our study, 52 neonates were randomized and completed the study (Figure 1), and the results were analyzed with the intention of health promotion and treatment. Demographic characteristics were similar between the two groups (Table 1). Primary outcomes were clearly different between two groups. Two infants (7.7%) in the aminophylline group developed apnea, as compared to 16 infants (61.5%) in the control group (P < 0.001; Table 2). Three and four neonates (11.5%, 15.4%) in the aminophylline group developed bradycardia and cyanosis respectively, as compared to 16 infants (61.5%) in the control group (P < 0.001; Table 2).

Bottom Line: Three and four neonates (11.5%, 15.4%) in the aminophylline group developed bradycardia and cyanosis respectively, as compared to 16 infants (61.5%) who did not receive aminophylline (P < 0.001).No side effects were reported in neonates (P > 0.999).In other words, the more premature an infant, the greater the preventative effect of aminophylline on the incidence of apnea and bradycardia.

View Article: PubMed Central - PubMed

Affiliation: Department of Pediatrics, Child Growth and Development Research Center, Isfahan University of Medical Sciences, Isfahan, IR Iran.

ABSTRACT

Background: A few studies have been carried on preventive drugs for apnea of preterm neonates.

Objectives: This study aimed to assess the safety and prophylactic effects of aminophylline on the incidence of apnea in premature neonates.

Patients and methods: This study was a randomized clinical trial (RCT) research. The prophylactic effect of aminophylline on apnea was investigated in premature babies in our NICU (IRAN-Isfahan). In the study group (A), 5 mg/kg aminophylline was initially administered as a loading dose. Then, every 8 hours, 1.5 mg/kg was given as maintenance dose for the next 10 days. In the control group (C), no aminophylline was used during the first ten days of life.

Results: Fifty-two neonates were randomized for the study and all of them completed it. Primary outcomes were clearly different between the two groups. Only 2 infants (7.7%) who had been placed in aminophylline group developed apnea, as compared to 16 infants (61.5%) in the control group (P < 0.001). Three and four neonates (11.5%, 15.4%) in the aminophylline group developed bradycardia and cyanosis respectively, as compared to 16 infants (61.5%) who did not receive aminophylline (P < 0.001). Median time of need to NCPAP (Nasal Continuous Positive Airway Pressure) was 1 (0 - 4) days and 2.5 (0.5 - 6.5) days in group A and C, respectively (P = 0.03). No side effects were reported in neonates (P > 0.999). Median time of hospitalization was shorter in aminophylline group (P = 0.04).

Conclusions: This study supports the preventative effects of aminophylline on apnea in extreme premature infants. In other words, the more premature an infant, the greater the preventative effect of aminophylline on the incidence of apnea and bradycardia.

No MeSH data available.


Related in: MedlinePlus